Ifosfamide (IFO) is a highly effective chemotherapeutic agent for treating a variety of pediatric solid tumors. However, its use is limited due to its serious side effect on kidneys. The side-chain oxidation of IFO in renal tubular cells produces a reactive toxic metabolite that is believed to be responsible for its nephrotoxic effect. Therefore, this study was carried out to investigate the possible underlying mechanisms that may be involved in IFO-induced nephrotoxicity, including free radical generation and the possible role of alpha lipoic acid (ALA) versus N-acetylcysteine (NAC) in protection against this toxicity. Male albino rats were injected intraperitoneally with saline, IFO (50 mg/kg daily for 5 days), IFO + ALA (100 mg/kg daily for 8 days) and IFO + NAC (200 mg/kg daily for 8 days). Kidney malondialdehyde, nitric oxide and glutathione contents and serum biochemical parameters and histopathological analysis were determined. Both ALA and NAC markedly reduced the severity of renal dysfunction induced by IFO. NAC was more nephroprotective than ALA. This study suggests that oxidative stress is possibly involved in the IFO-induced nephrotoxicity in rats. The study also suggests the potential therapeutic role for ALA and NAC against IFO-induced nephrotoxicity.
AleksaKHalachmiNItoSKorenG (2005) A tubule cell model for ifosfamide nephrotoxicity. Canadian Journal of Physiology and Pharmacology83: 499–508.
2.
Al-GhonaimMPannuN (2006) Prevention and treatment of contrast-induced nephropathy. Techniques in Vascular and Interventional Radiology9: 42–49.
3.
BadaryOA (1998) Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncology Research10: 355–360.
4.
BadaryOA (1999a) l-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Experimental Nephrology7: 323–327.
5.
BadaryOA (1999b) Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. Journal of Ethnopharmacology67: 135–142.
6.
BaeELeeJKimS (2007) Effects of antioxidant drugs in rats with acute renal injury. Evidence Based Practice5: 23–27.
7.
BenvenutoAAyeleWLeghaSRaberNNicaiseCNewmanA (1992) Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine. Anticancer Drugs3: 19–23.
8.
ChenNAleksaKWoodlandCRiederMKorenG (2007) The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Translational Research150(1): 51–57.
9.
ChenNAleksaKWoodlandCRiederMKorenG (2008) N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. British Journal of Pharmacology153(7): 1364–1372.
10.
De FloraSIzzottiAD'AgostiniFCesaroneC (1991) Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. American Journal of Medicine91: 122–130.
11.
De VriesNDe FloraS (1993) N-Acetyl-l-cysteine. Journal of Cellular Biochemistry17: 270–277.
12.
DickeyDWuYMuldoonLNeuweltE (2005) Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. Journal of Pharmacology and Experimental Therapeutics314(3): 1052–1058.
13.
DuruMNacarAYöndenZKuvandıkGHelvacıRKoçA. (2008) Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Renal Failure30(4): 453–459.
14.
EllmanG (1959) Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics82: 70–77.
15.
EsterbauerHSchaurJZollnerH (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine11: 81–128.
16.
GoligorskySBrodskyVNoiriE (2002) Nitric oxide in acute renal failure: NOS versus NOS. Kidney International61: 855–861.
17.
GossmannJRadounikliABernemannASchellinskiORaabPBickebollerR (2001) Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide. Kidney and Blood Pressure Research24: 111–115.
18.
HaleagraharaNYeeTChakravarthiSLeeN (2009) Protective effect of N-acetylcysteine on cyclosporine A-induced changes in lipid hydroperoxide levels and renal dysfunction in rats. Archives of Medical Science5: 16–22.
19.
IzzedineHLaunay-VacherVIsnard-BagnisCDerayG (2003) Drug-induced Fanconi's syndrome. American Journal of Kidney Diseases41: 292–309.
20.
KaganEShvedovaASerbinovaEKhanSSwansonCPowellR. (1992) Dihydrolipoic acid a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl, and chromanoxyl radicals. Biochemical Pharmacology44: 1637–1649.
21.
KangKKimDJungYLeeALeeSLeeS. (2009) Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrology Dialysis Transplantation24(10): 3012–3020.
22.
KellyG (1998) Clinical applications of N-acetylcysteine. Alternative Medicine Review3: 114–127.
23.
LeveySPerroneDMadiasE (1988) Serum creatinine and renal function. Annual Review of Medicine39: 465–490.
24.
LoebsteinRKorenG (1998) Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics101: E8–E12.
25.
LoebsteinRAtanackovicGBishaiRWolpinJKhattakSHashemiG. (1999) Risk factors for long-term outcome of ifosfamide induced nephrotoxicity in children. Journal of Clinical Pharmacology39: 454–461.
26.
MaddaiahT (1990) Glutathione correlates with lipid peroxidation in liver mitochondria of triiodothyronine-injected hypophysectomized rats. Federation of American Societies for Experimental Biology Journal4: 1513–1518.
27.
MalarkodiKBalachandarAVaralakshmiP (2003) The influence of lipoic acid on adriamycin induced nephrotoxicity in rats. Molecular and Cellular Biochemistry247(1–2): 15–22.
28.
MarzulloL (2005) An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Current Opinion in Pediatrics17: 239–245.
29.
MirandaKEspeyMWinkD (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide: Biology and Chemistry5: 62–71.
30.
MishimaKBabaAMatsuoMItohYOishiR (2006) Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radical Biology and Medicine40: 1564–1577.
31.
MoiniHPackerLSarisN (2002) Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Toxicology and Applied Pharmacology182: 84–90.
32.
MorganRDonleyJHarrisonFHunterL (1982) The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung. Seminars in Oncology9: 71–74.
33.
NicholsW (1997) α-Lipoic acid: biological effects and clinical implications. Alternative Medicine Review2(3): 177–183.
34.
NissimIWeinbergJ (1996) Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney International49: 684–695.
35.
NitescuNRickstenSMarcussenNHaraldssonBNilssonUBasuS. (2006) N-Acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia–reperfusion. Nephrology, Dialysis, Transplantation21: 1240–1247.
36.
PackerLWittETritschlerH (1995) Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine19: 227–250.
37.
PeresleniTNoiriEBahouWGoligorskyM (1996) Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. American Journal of Physiology270: F971–F977.
38.
RossiRPleyerJSchafersPKuhnNKletaRDeufelT. (1999) Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Medical and Pediatric Oncology32: 177–182.
39.
RoySPackerL (1998) Redox regulation of cell functions by alpha-lipoate: biochemical and molecular aspects. Biofactors7: 263–267.
40.
SehirliOSakarcanAVelioglu-OguncACetinelSNursalGYegenC. (2007) Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicology and Applied Pharmacology222: 33–41.
41.
SenerGSehirliOYegenBCetinelSGedikNSakarcanA (2004) Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. Journal of Pineal Research37: 17–25.
42.
SkinnerR (2003) Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology41: 190–197.
43.
SkinnerRPearsonAPriceLCoulthardMCraftA (1990) Nephrotoxicity after ifosfamide. Archives of Diseases in Childhood65(7): 732–738.
44.
SkinnerRSharkeyIPearsonACraftA (1993) Ifosfamide, mesna, and nephrotoxicity in children. Journal of Clinical Oncology11: 173–190.
45.
SmithAShenviSWidlanskyMSuhJHagenT (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medical Chemistry11: 1135–1146.
46.
SomaniSHusainKWhitworthCTrammellGMalafaMRybakP (2000) Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacology and Toxicology86(5): 234–241.
47.
SpringateJ (1997) Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. Journal of Applied Toxicology17: 75–79.
48.
SpringateJChanKLuHDaviesSTaubM (1999) Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cellular and Developmental Biology Animal35: 314–317.
49.
StrakaCHebartHAdler-ReichelSWerdingNEmmerichBEinseleH (2003) Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. Oncology65(Suppl 2): 94–98.
50.
TakaokaMOhkitaMKobayashiYYubaMMatsumuraY (2002) Protective effect of α-lipoic acid against ischaemic acute renal failure in rats. Clinical and Experimental Pharmacology and Physiology29: 189–194.
TylickiLRutkowskiBHorlW (2003) Antioxidants: a possible role in kidney protection. Kidney and Blood Pressure Research26: 303–314.
53.
WoodlandCItoSGranvilCWainerIKleinJKorenG (2000) Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Science68: 109–111.
54.
YazawaYTakagiTAsakuraSSuzukiKKanoY (1999) Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. Journal of Orthopaedic Science4(3): 231–237.
55.
YoshiokaTKawadaKShimadaTMoriM (1979) Lipid peroxidation in maternal and cord blood and protective mechanism against activated oxygen toxicity in the blood. American Journal of Obstetrics and Gynecology135: 372–376.
